Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 versus PPSV23 pneumococcal vaccination in untreated chronic lymphocytic leukemia
2009-012642-22Phase 3Active
- Sponsor
- Swedish CLL Group
- Start
- Oct 2009
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in pneumococcal disease comparing Prevenar arm with Pneumovax arm (2 arms). Primary endpoint: Positive vaccination response by OPA at 1 month. Started Oct 2009; status: active.
02
Drugs
pneumococcal 7-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2009-012642-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012642-22.